COMBINATION OF DAROLUTAMIDE WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL INCREASES SURVIVAL FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN THE PHASE 3 ARASENS STUDY

被引：0
|
作者：
Olivier, Kara [1 ]
Tombal, Betrand [2 ]
Thiele, Silke [3 ]
Li, Rui [4 ]
Joensuu, Heikki [5 ]
Smith, Matthew [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Clin Univ St Luc, Brussels, Belgium
[3] Bayer AG, Berlin, Germany
[4] Bayer HealthCare Inc, Whippany, NJ USA
[5] Orion Pharma, Espoo, Finland
来源：
ONCOLOGY NURSING FORUM | 2022年 / 49卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P386
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF ADDING DAROLUTAMIDE TO DOCETAXEL AND ANDROGEN DEPRIVATION THERAPY IN THE TREATMENT OF METASTATIC HORMONE-SENSITIVE PROSTRATE CANCER
    Nwogu, I. B.
    Nedzesky, J.
    Carlson, J. J.
    VALUE IN HEALTH, 2023, 26 (06) : S106 - S106
  • [32] Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer
    Chen, Kenneth
    McVey, Aoife
    Kasivisvanathan, Veeru
    Jenjitranant, Pocharapong
    Azad, Arun
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2022, 82 (01) : 146 - 147
  • [33] Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer
    Olivier, Timothee
    Tsantoulis, Petros
    Prasad, Vinay
    EUROPEAN UROLOGY, 2023, 83 (06) : 584 - 585
  • [34] Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
    Saad, Fred
    Hussain, Maha H. A.
    Tombal, Bertrand
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Nordquist, Luke T.
    Bogmann, Martin
    Tutrone, Ronald
    Shore, Neal D.
    Belkoff, Laurence
    Fralich, Todd
    Jhaveri, Jay
    Srinivasan, Shankar
    Li, Rui
    Verholen, Frank
    Kuss, Iris
    Smith, Matthew R.
    EUROPEAN UROLOGY, 2024, 86 (04) : 329 - 339
  • [35] Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study.
    Wang, Shanshan
    Fu, Cheng
    Zou, Qing
    Li, Youyuan
    He, Dalin
    Wang, Shaogang
    Wang, Hongkai
    Smith, Matthew Raymond
    Tombal, Bertrand F.
    Hussain, Maha H. A.
    Niu, Yi
    Cai, Ling
    Hu, Nan
    Huang, Shiyun
    Kapur, Shivani
    Li, Rui
    Kuss, Iris
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Re: Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2022, 208 (01): : 215 - 216
  • [37] Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population
    Gupta, Alok
    Hussain, Shaik Maheboob
    Sonthwal, Neha
    Chaturvedi, Harit
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (02) : 389 - 392
  • [38] Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer
    Sathianathen, Niranjan J.
    Oestreich, Makinna C.
    Brown, Sarah Jane
    Gupta, Shilpa
    Konety, Badrinath R.
    Dahm, Philipp
    Kunath, Frank
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (12):
  • [39] Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
    Hu, Linjun
    Zhao, Qinxin
    Bai, Hongsong
    Xie, Chengming
    Shan, Xingli
    Lu, Dehu
    Chen, Yonghai
    Han, Dongdong
    Xiao, Zejun
    Tian, Jun
    Wang, Dong
    Bi, Xingang
    Xing, Nianzeng
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4369 - 4377
  • [40] Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study.
    Hussain, Maha H. A.
    Tombal, Bertrand F.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Shore, Neal D.
    Kopyltsov, Evgeny
    Rezazadeh, Arash
    Boegemann, Martin
    Ye, Ding-Wei
    Cruz, Felipe Melo
    Suzuki, Hiroyoshi
    Kapur, Shivani
    Srinivasan, Shankar
    Verholen, Frank
    Kuss, Iris
    Joensuu, Heikki
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345